Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin for Glucose Fluctuation and Immunosenescence in T2DM (HOLIDYA)
NCT06818851Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Henagliflozin Group with Placebo Group (2 arms). Primary endpoint: Mean Amplitude of Glycemic Excursions at 16 weeks. Started Jul 2025; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06818851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818851.